From Drugs Controller General of India
AstraZeneca Pharma India has received Import and Market permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Acalabrutinib 100mg capsules (Calquence).The receipt of this Import and Market permission paves way for the launch of Acalabrutinib 100mg capsules (Calquence) in India, subject to the receipt of related statutory approvals and licenses.
Acalabrutinib 100mg capsules is indicated for treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
